Design Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 5, 2024
DSGN$10.80+5.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(in thousands, except share data)
| Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||||
| Shares · Amount · Capital · Income (Loss) · Deficit · Equity | ||||||||
| March 31, 2024 | 56,494,271 | $6 | $458,449 | $(167) | $(188,731) | $269,557 | ||
| Exercises of stock options | 6,392 | — | 6 | — | — | 6 | ||
| Issuance of common stock under employee stock purchase plan | 119,351 | 223 | 223 | |||||
| Stock-based compensation | — | — | 3,299 | — | — | 3,299 | ||
| Unrealized loss on investments | — | — | — | (50) | — | (50) | ||
| Net loss | — | — | — | — | (11,793) | (11,793) | ||
| Balance at June 30, 2024 | 56,620,014 | $6 | $461,977 | $(217) | $(200,524) | $261,242 | ||
| Balance at December 31, 2023 | 56,473,598 | $6 | $455,245 | $62 | $(177,626) | $277,687 | ||
| Exercises of stock options | 27,065 | — | 26 | — | — | 26 | ||
| Issuance of common stock under employee stock purchase plan | 119,351 | — | 223 | — | — | 223 | ||
| Stock-based compensation | — | — | 6,483 | — | — | 6,483 | ||
| Unrealized loss on investments | — | — | — | (279) | — | (279) | ||
| Net loss | — | — | — | — | (22,898) | (22,898) | ||
| Balance at June 30, 2024 | 56,620,014 | $6 | $461,977 | $(217) | $(200,524) | $261,242 | ||
| Balance at March 31, 2023 | 55,919,561 | $6 | $444,852 | $(1,982) | $(130,058) | $312,818 | ||
| Exercises of stock options and vesting of restricted stock | 24,091 | — | 7 | — | — | 7 | ||
| Issuance of common stock under employee stock purchase plan | 35,547 | — | 206 | — | — | 206 | ||
| Stock-based compensation | — | — | 3,719 | — | — | 3,719 | ||
| Unrealized loss on investments | — | — | — | (18) | — | (18) | ||
| Net loss | — | — | — | — | (19,937) | (19,937) | ||
| Balance at June 30, 2023 | 55,979,199 | $6 | $448,784 | $(2,000) | $(149,995) | $296,795 | ||
| Balance at December 31, 2022 | 55,895,596 | $6 | $441,424 | $(3,356) | $(110,764) | $327,310 | ||
| Exercises of stock options and vesting of restricted stock | 48,056 | — | 9 | — | — | 9 | ||
| Issuance of common stock under employee stock purchase plan | 35,547 | — | 206 | — | — | 206 | ||
| Stock-based compensation | — | — | 7,145 | — | — | 7,145 | ||
| Unrealized gain on investments | — | — | — | 1,356 | — | 1,356 | ||
| Net loss | — | — | — | — | (39,231) | (39,231) | ||
| Balance at June 30, 2023 | 55,979,199 | $6 | $448,784 | $(2,000) | $(149,995) | $296,795 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.